U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07250984) titled 'Treatment of Atypical Resistant Facial Pain' on Nov. 18.
Brief Summary: Facial pain in the trigeminal nerve region, which is not a migraine headache is often very persistent and difficult to treat. Research findings suggest that, similar to the mechanisms of migraine headache, the increased concentration of calcitonin gene-related peptide (CGRP) plays an important role in the mechanisms of facial pain.
Therefore, we hypothesize that intravenous administration of ACMP will similarly disrupt central sensitization in facial pain as it does in migraine headaches.
Study Start Date: Nov. 03
Study Type: OBSERVATIONAL
Condition:
Facial...